Landscapes / Companies
Miltenyi Biomedicine GmbH not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 in Phase 2
Drugs
3
in active trials · 4 in all
Trials
11 active
13 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Gene therapy substances |
Phase 2 | 31 Dec 2026Phase 2 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Mantle Cell Lymphoma (MCL), CAR T Cell Therapy and 16 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Sep 2027Phase 1/2 trial completes | |||
| Next date | 30 Sep 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent and 8 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jun 2028Phase 1/2 trial completes | |||
| Next date | Jun 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Leukemia, Myeloid, Acute | ||||
| Open drug page | |||||
About
- No active trial
- MB-CART20.1
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021